| Execution period | 36 months from 04-11-2026 |
|---|
BSE filing, NSE: LALPATHLAB. Summary written from the filing by ALFA Finder's alert engine.
Dr. Lal Pathlabs Ltd: key numbers
- Share price
- ₹2,045.00
- Market cap
- ₹34,325 Cr
- Revenue (annual)
- ₹2,763 Cr
- Net profit (annual)
- ₹504.8 Cr
- P/E (TTM)
- 58.8×Sector 53.8×
- Promoter holding
- 52.93%-0.26% QoQ
- FII holding
- 18.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Lal Pathlabs Ltd
All →Dr. Lal Pathlabs Capital Structure Change
Dr. Lal PathLabs will invest up to Rs 49.5 Crore in its wholly owned Dubai subsidiary, in tranches. Funds cover operations and further investment in Ghana's SHL.
- Value
- ₹49.50 Cr
- Execution
- Indicative completion by 31 March 2027, in tranches
Dr. Lal Pathlabs Dividend
Dr. Lal Path Labs approved a Rs 5 per share second interim dividend. Record date is November 11, 2026; payment by December 3, 2026.
Dr. Lal Pathlabs Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 874 Cr (+19.6%), EBITDA Rs 280 Cr (32.1% margin), PAT Rs 194 Cr (+27.5%). Strategy: AI diagnostics, rural GraminFit, M&A.
Dr. Lal Pathlabs Q2 FY27 Results: Net Profit ₹193.9 Cr, Up 27.4% YoY
Dr. Lal Pathlabs Ltd reported revenue from operations of ₹873.9 Cr (+19.6% YoY) and net profit of ₹193.9 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹193.9 Cr · +27.4% YoY
Dr. Lal Pathlabs Board Meeting Date
Dr. Lal PathLabs updated its 4 November 2026 board meeting notice to add a possible second interim dividend. The meeting will also approve unaudited quarterly results.
Dr. Lal Pathlabs Acquisition Worth ₹30.3 Cr
Dr. Lal PathLabs subscribed to WOS PUPL equity to fund PUPL's buyout of remaining 30% in CentraPath Labs for ₹30.3 Crore. CentraPath becomes a wholly owned subsidiary.
- Value
- ₹30.30 Cr
Other management change announcements
All →Aluwind Infra-Tech Management Change
Aluwind Infra-Tech appointed Ajay Porwal as Senior Management Personnel, effective 5 November 2026, to expand export business. Unaudited half-year results were also approved.
HEG Advanced Materials Management Change
HEG Advanced Materials appointed Hiren Pravin Shah and Ankur Khaitan as Senior Management Personnel, effective 3 November 2026. Both appointments were disclosed under the change in management category.
GMM Pfaudler Management Change
GMM Pfaudler appointed Ankit Nayyar as Group Chief Financial Officer effective 4 November 2026, after he served as Deputy CFO from May 2026. Alexander Poempner resigned as CFO effective 3 November 2026, citing personal exigencies.
Thangamayil Jewellery Management Change
Thangamayil Jewellery appointed K. Thiagarajan as Non-Executive Independent Director and B. Rajesh Kanna as Executive Director, both effective November 4, 2026. Each has a 60-month term.
CHD Chemicals Management Change
CHD Chemicals redesignated Ankit Kothari as Executive Director and Mahtab Singh as Non-Executive Non-Independent Director. Kothari's change is effective 4 November 2026.
Marc Technocrats Management Change
Marc Technocrats appointed Gaurav Kaushik as Chief Financial Officer. The appointment is effective November 4, 2026, per the filing.